<DOC>
	<DOCNO>NCT00667329</DOCNO>
	<brief_summary>The goal clinical research study see well drug 2CdA , cyclophosphamide , rituximab ( rituxan ) shrink lymphoma call Waldenstrom 's macroglobulinemia . After drug give 2 course , second goal see long remission last . A third goal see often repeat remission achieve lymphoma return later drug restart .</brief_summary>
	<brief_title>Treatment Macroglobulinemic Lymphoma With 2CdA , Cyclophosphamide Rituximab</brief_title>
	<detailed_description>Before study start , patient complete exam . Blood urine test do . A bone marrow test , chest x-ray CT scan abdomen do study recently . Blood test repeat 14 , 21 , 42 day . Provided disease respond , another bone marrow sample take confirm remission . X-rays may repeat reason . The patient family member taught inject 2CdA skin three time day 7 day . The patient also take cyclophosphamide mouth twice day . Rituxan give vein weekly 4 week test infusion day prior first injection . A second course 3 drug give 6 week start first course . All patient improve disease follow without treatment . This investigational study . The FDA approve drug treatment low-grade lymphoma . The combine use drug Waldenstrom 's macroglobulinemia investigational , although drug effective disease . About 50 patient take part study . This study take place UTMDACC ( outpatient basis ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>2-chloro-3'-deoxyadenosine</mesh_term>
	<criteria>1 . Newly diagnose patient symptomatic macroglobulinemic lymphoma eligible . Macroglobulinemic lymphoma include patient either biopsy proven small lymphocytic lymphoma chronic lymphocytic leukemia monoclonal IgM . Also include symptomatic patient clonal proliferation produce pathologic monoclonal IgM cause cryoglobulinemia , peripheral neuropathy cold agglutinin hemolytic anemia . 2 . Patients must adequate liver function ( bilirubin &lt; 2.5 mg % ) renal function ( creatinine &lt; 2.0 mg % ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Waldenstrom 's Macroglobulinemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>2CdA</keyword>
	<keyword>Cladribine</keyword>
	<keyword>Leustatin</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Rituximab</keyword>
</DOC>